Patent · US Active

Methods and compositions for the treatment of Sengers syndrome

US11931397B2 · kind B2 · utility

0Cited by

0References

24Claims

0Family size

Assignee

Stealth BioTherapeutics Inc. · MC

Inventors

James Carr · Cos Cob, US
Michael Dimatteo · Newton, US
Anthony Abbruscato · Newton, US
Hans Bjornsson · Grundarhverfi, IS

Key dates

Filing date	Dec 5, 2019
Grant date	Mar 19, 2024
Priority date	—
Expiry date	Jan 2, 2041

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K5/1019
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The disclosure provides methods of preventing or treating Sengers syndrome in a mammalian subject, reducing risk factors associated with Sengers syndrome, and/or reducing the likelihood or severity of Sengers syndrome. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to increase expression of AGK in subjects in need thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.